HR0124LRB104 10582 LAW 20658 r HR0124 LRB104 10582 LAW 20658 r
HR0124 LRB104 10582 LAW 20658 r
1 HOUSE RESOLUTION
2 WHEREAS, Serious mental illnesses like bipolar disorder,
3 major depressive disorder, and schizophrenia often require
4 treatment with antipsychotic medications for effective
5 management, and antipsychotic prescribing rates continue to
6 rise; and
7 WHEREAS, While prolonged antipsychotic use may be
8 essential for the treatment of certain conditions, it is
9 associated with tardive dyskinesia (TD), a condition marked by
10 uncontrollable, abnormal, and repetitive movements of the
11 face, torso, limbs, or extremities; and
12 WHEREAS, People at higher risk of TD include those older
13 than 55 years, people who are Black, women, individuals with
14 mood or substance use disorders, intellectual disabilities, or
15 central nervous system injuries, and those with high
16 cumulative antipsychotic exposure; and
17 WHEREAS, Approximately 60% of the estimated 800,000 U.S.
18 adults living with TD remain undiagnosed, and even mild TD
19 symptoms can be stigmatizing and impair physical, social, and
20 emotional well-being, underscoring the urgency of early
21 screening, detection, and intervention; and
HR0124 LRB104 10582 LAW 20658 r
HR0124- 2 -LRB104 10582 LAW 20658 r HR0124 - 2 - LRB104 10582 LAW 20658 r
HR0124 - 2 - LRB104 10582 LAW 20658 r
1 WHEREAS, The American Psychiatric Association recommends
2 routine TD screening in their clinical guidelines for
3 antipsychotic treatment, and individuals treated with
4 antipsychotics or experiencing abnormal movements should
5 consult their health care providers to assess TD risk, receive
6 TD screenings, and determine appropriate treatment together;
7 and
8 WHEREAS, FDA-approved treatments for TD can provide
9 options for symptom management and improved quality of life
10 for many individuals living with TD; and
11 WHEREAS, The General Assembly can encourage TD screening
12 education and awareness for health care providers, patients,
13 and care partners to help ensure patients prescribed
14 antipsychotics receive care and support that aligns with
15 clinical best practices, including regular TD screenings;
16 therefore, be it
17 RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE
18 HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that
19 we declare May 4 through May 10, 2025 as Tardive Dyskinesia
20 Awareness Week (TDAW) in the State of Illinois; and be it
21 further
22 RESOLVED, That we support TDAW in recognition of the
HR0124 - 2 - LRB104 10582 LAW 20658 r
HR0124- 3 -LRB104 10582 LAW 20658 r HR0124 - 3 - LRB104 10582 LAW 20658 r
HR0124 - 3 - LRB104 10582 LAW 20658 r
HR0124 - 3 - LRB104 10582 LAW 20658 r